PP
BCRX icon

PDT Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

PDT Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$245K Sell
24,489
-538,951
-96% -$4.87M 0.01% 458
2026
Q1 		$5.36M Sell
563,440
-119,976
-18% -$932K 0.32% 101
2025
Q4 		$5.33M Hold
683,416
– – 0.35% 89
2025
Q3 		$5.19M Hold
683,416
– – 0.33% 98
2025
Q2 		$6.12M Sell
683,416
-95,313
-12% -$888K 0.35% 69
2025
Q1 		$5.84M Buy
778,729
+256,439
+49% +$2.07M 0.41% 45
2024
Q4 		$3.93M Buy
522,290
+10
+0% +$76 0.35% 78
2024
Q3 		$3.97M Buy
522,280
+155,510
+42% +$1.18M 0.35% 60
2024
Q2 		$2.27M Sell
366,770
-13,753
-4% -$75.9K 0.21% 173
2024
Q1 		$1.93M Buy
380,523
+69,325
+22% +$390K 0.18% 198
2023
Q4 		$1.86M Buy
311,198
+40,489
+15% +$235K 0.21% 159
2023
Q3 		$1.92M Buy
270,709
+71,630
+36% +$515K 0.24% 138
2023
Q2 		$1.4M Buy
199,079
+88,626
+80% +$711K 0.19% 183
2023
Q1 		$921K Buy
110,453
+49,573
+81% +$477K 0.12% 280
2022
Q4 		$699K Sell
60,880
-3,269
-5% -$40.8K 0.11% 324
2022
Q3 		$808K Buy
+64,149
New +$826K 0.12% 285
2020
Q3 		– Sell
-86,518
Closed -$412K – 724
2020
Q2 		$412K Buy
+86,518
New +$346K 0.03% 455
2017
Q3 		– Sell
-129,200
Closed -$718K – 519
2017
Q2 		$718K Hold
129,200
– – 0.03% 370
2017
Q1 		$1.08M Sell
129,200
-1,594
-1% -$11.1K 0.06% 312
2016
Q4 		$828K Sell
130,794
-31,106
-19% -$162K 0.05% 350
2016
Q3 		$714K Buy
+161,900
New +$647K 0.04% 342
2015
Q3 		– Sell
-74,960
Closed -$1.12M – 1268
2015
Q2 		$1.12M Buy
+74,960
New +$852K 0.03% 706
2014
Q4 		– Sell
-70,474
Closed -$689K – 657
2014
Q3 		$689K Sell
70,474
-30,040
-30% -$368K 0.02% 838
2014
Q2 		$1.28M Buy
100,514
+60,540
+151% +$589K 0.03% 607
2014
Q1 		$423K Sell
39,974
-51,126
-56% -$545K 0.01% 1021
2013
Q4 		$692K Buy
91,100
+57,043
+167% +$361K 0.08% 311
2013
Q3 		$248K Buy
+34,057
New +$173K 0.01% 1328

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PDT Partners's BCRX Position: Q2 2026 in Review

PDT Partners reduced its BioCryst Pharmaceuticals (BCRX) stake by 96% in Q2 2026, selling an estimated $4.87M and leaving 24,489 shares worth $245K. The position accounts for 0.01% of the portfolio, ranked #458.

PDT Partners first reported a position in BCRX in Q3 2013 and has held it in 27 quarters since. The position peaked at $6.12M in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • PDT Partners held 24,489 shares of BioCryst Pharmaceuticals worth $245K as of Q2 2026.
  • PDT Partners sold 538,951 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $4.87M.
  • BioCryst Pharmaceuticals made up 0.01% of PDT Partners's portfolio in Q2 2026, its #458 holding.
  • PDT Partners first reported a position in BioCryst Pharmaceuticals in Q3 2013 and has held it in 27 quarters since.
  • PDT Partners's BioCryst Pharmaceuticals position peaked at $6.12M in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.